Sources sought
Audit & Recall Indefinite Delivery Indefinite Quantity (IDIQ) Contract
75F40124R00041
Food and Drug Administration, FDA Office of Acq Grant SVCS. All Other Support Services.
Response deadline
March 7, 2024 at 2:00 PM EST
Closed 969 days ago. Posted February 22, 2024. Scheduled to archive March 22, 2024.
Get the next one like this from Food and Drug Administration by email, the day it is posted.Find my opportunities
This one closed in 2024
11 like it are open now in all other support services
- PBUSE PERSONNEL CONTRACT FOLLOW ON
Department of the Army, 0409 Aq HQ Contract
SolicitationNAICS 561990Location not publishedW912PB26RA038Closes in 2 daysNov 3 - 125 IN BN Pre Deployment Yellow Ribbon November 2026
Department of the Army, W7NF Uspfo Activity Mi Arng
Combined synopsis and solicitationSmall businessNAICS 561990Novi, MIW912JB27QA001Closes in 2 daysNov 3 - Houston Doc Destruction Service (Shredding)
Department of Veterans Affairs, 256-Network Contract Office 16
Sources soughtNAICS 561990Texas36C25627Q0089Closes in 2 daysNov 3
Description
As published on SAM.gov.
The Food and Drug Administration (FDA) protects public health by coordinating, initiating, and/or monitoring regulatory and recall actions, reviewing and managing compliance policies and processes, and evaluating data to assess and enhance agency compliance activities. The Office of Regulatory Affairs (ORA) within FDA has substantially evolved its product safety and quality model to keep ahead of the possible risks in an ever-changing world of manufacturers and producers.
While import growth, rates have accelerated, so too has the need for highly standardized operations within the government and the marketplace. The new global implications have forced FDA to recognize major implications such as pressures to reduce cost, increase productivity and capitalize on quality improvement activities while maintaining strong global safety standards.
The Code of Federal Regulations (CFR) Title 21 Part 7 (21CFR7) governs the practices and procedures applicable to regulatory enforcement actions initiated by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and other laws that it administers. A recall is a firm's removal or correction of a marketed product that the FDA considers to be in violation of the laws it administers.
A correction is further defined as the repair, modification, adjustment, relabeling, destruction, or inspection (including patient monitoring) of a product without its physical removal to some other location. Any firm may initiate a recall when its product is deemed to be in violation of FDA regulations and laws.
Throughout the execution of a recall, it is the FDA’s responsibility to provide guidance to recalling firms, determine the hazard posed by the recalled product, inform the public of potential health risks, and monitor firms’ recall effectiveness, in part, by conducting recall audit checks (RACs) at recalling firm’s consignees to determine whether the consignee received the recall notification and followed instructions in the notification.
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
February 22, 2024
Sources sought
Due March 7, 2024 at 2:00 PM EST. SAM.gov, notice 3b3c103149c240c3a42867af923287dd
Points of contact
- Amanda LuskAmanda.Lusk@fda.hhs.gov2404020264
- Nicholas BisherNicholas.Bisher@fda.hhs.gov2404022773